-+ 0.00%
-+ 0.00%
-+ 0.00%

Jefferies published a research report saying that Kangfang Biotech's IVO delayed entering the US market due to receiving a complete response letter, but the bank believes that the investment argument is still complete, and that non-small cell lung cancer accounts for only a small portion of IVO's global potential due to second-line eGFR mutations. The market's prudent expectations for Harmoni-3 created upside. The bank pointed out that Kang Fang Biotech indicated that on-site inspections at the clinical trial site in China and production facilities in Guangzhou had passed, indicating that the key problem was that the overall survival period was not statistically significant, rather than data quality, production, or new safety issues. The bank believes that fundamental damage is limited, and IVO's broader global opportunities are still there. The US team estimates that this indication can reach only about 8,000 patients per year, with unadjusted peak sales of about 400 million US dollars. Compared with IVO's total unadjusted peak sales of 17.2 billion US dollars, most of it comes from first-line non-small cell lung cancer. More importantly, Harmoni-6/2 then handed over a statistically significant OS risk ratio of 0.66/0.73 compared to tiralizumab and pembrolizumab controls, respectively, supporting the biological basis of PD-1/VEGF. The bank maintained Kangfang Biotech's “buy” rating and target price of HK$226.

Zhitongcaijing·11/16/2026 06:25:04
Listen to the news
Jefferies published a research report saying that Kangfang Biotech's IVO delayed entering the US market due to receiving a complete response letter, but the bank believes that the investment argument is still complete, and that non-small cell lung cancer accounts for only a small portion of IVO's global potential due to second-line eGFR mutations. The market's prudent expectations for Harmoni-3 created upside. The bank pointed out that Kang Fang Biotech indicated that on-site inspections at the clinical trial site in China and production facilities in Guangzhou had passed, indicating that the key problem was that the overall survival period was not statistically significant, rather than data quality, production, or new safety issues. The bank believes that fundamental damage is limited, and IVO's broader global opportunities are still there. The US team estimates that this indication can reach only about 8,000 patients per year, with unadjusted peak sales of about 400 million US dollars. Compared with IVO's total unadjusted peak sales of 17.2 billion US dollars, most of it comes from first-line non-small cell lung cancer. More importantly, Harmoni-6/2 then handed over a statistically significant OS risk ratio of 0.66/0.73 compared to tiralizumab and pembrolizumab controls, respectively, supporting the biological basis of PD-1/VEGF. The bank maintained Kangfang Biotech's “buy” rating and target price of HK$226.